Cohort study shows anakinra and canakinumab reduce disease activity in pediatric patients, indicating potential for effective treatment.
In this pediatric cohort of cr-FMF patients, both anakinra and canakinumab were effective in reducing disease activity and inflammation. Anakinra offered rapid symptom relief but had frequent injection site reactions. Canakinumab provided sustained control with fewer local side effects but required monitoring for rare complications.
No takes yet. Share an insight, caveat, or question.
Arslan et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: